The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Merck Serono
Consulting or Advisory Role - Merck Serono
Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age.
 
Stephan Sahm
Stock and Other Ownership Interests - Fresenius; Merck KGaA
Honoraria - Fresenius
Research Funding - Merck Serono (Inst); Roche (Inst)
 
Thomas Goehler
No Relationships to Disclose
 
Christiane Hering-Schubert
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Mundipharma; Novartis; Pfizer
 
Jan Janssen
No Relationships to Disclose
 
Ulf Peter Neumann
No Relationships to Disclose
 
Michael Schwittay
No Relationships to Disclose
 
Mark-Oliver Zahn
Honoraria - Celgene
Consulting or Advisory Role - Novartis
 
Karsten Guenter Stenzel
Employment - Merck Serono
 
Alma Katharina Steinbach-Buechert
Employment - Merck KGaA (I); Merck Serono
 
Friedrich Overkamp
No Relationships to Disclose